Funding Acknowledgements Type of funding sources: None. Purpose. To estimate the effect of omega-3 polyunsaturated fatty acids (PUFAs) in prevention of postoperative atrial fibrillation (POAF) in patients with coronary artery disease undergoing coronary artery bypass graft (CABG) surgery. Methods. Studied were 306 patients who underwent CABG. All the patients were divided into two groups depending on the prescription of omega-3 PUFAs in the pre- and postoperative period by randomization method: 1 group comprised 158 patients without PUFAs (82.7% men, median age 63.0 (57.0;67.0) years, 2 group - 148 patients with PUFAs (89.3% men, median age 60.0 (57.0;64.0) years). PUFAs were prescribed 2000 mg daily starting with 5 days before CABG and 1000 mg daily after CABG for 21 days. In all the patients, we studied interleukin (IL)-6, IL-8, IL-10, NT-proBNP, troponin, superoxide dismutase (SOD), malondialdehyde (MDA), glutathione and omega-3 index. Results. During the observation period POAF occurred in 29.7% patients of group 1, and in 16.9% patients of group 2 (p = 0.009). In postoperative period patients of group 1 had median IL-6 level 39.3% higher (p = 0.001) and median IL-10 level - 20.2% higher (p = 0.01) comparing with group 2. In patients of group 2 we found SOD median level 78.9% lower (р<0.0001) and MDA median level 33.8% lower compared to the patients of group 1 (р=0.03). In postoperative period in group 2 the median level of docosahexaenoic acid was 55% higher (p = 0.03), and omega-3 index - 43.4% higher (h = 0.04) compared with group 1. Conclusion. We found that patients with PUFAs had less activation of inflammation and oxidative stress after CABG than patients without PUFAs. The patients with PUFAs also had increased levels of docosahexaenoic acids and omega-3 index compared to the patients without PUFAs. We also found a significant decrease of the prevalence of POAF after CABG in patients with PUFAs.

Dabigatran is highly effective oral anticoagulant used in patients with atrial fibrillation, venous thrombosis, pulmonary embolism, orthopedic surgery. The most important role in activation and transport of dabigatran play hepatic carboxylesterase-1 (CES-1) and P-glycoprotein. To date were studied different polymorphisms that affect the pharmacokinetics of dabigatran such as rs2244613 (C > A), rs8192935 (T > C) и rs71647871 (G > A), rs1128503 (1236 C > T), rs2032582 (2677 G > T), rs1045642 (3435 C > T) и rs4148738 (G > A) and others. At the same time, there is no need of dabigatran pharmacogenetics testing in routine care. On the other side, existing literature data is often controversial, that’s why future studies are needed to answer the above-mentioned question.

Introduction. Von Willebrand factor (vWF) is a large plasma glycoprotein that plays a major role in hemostasis. The vWF plasma concentration is not included in modern stoke risk stratification scales in patients with atrial fibrillation (AF).Aim — to evaluate the possibility of usage of vWF plasma concentration in stroke risk stratification in patients with atrial fibrillation.General findings. vWF is an important predictor of stroke development in patients with AF based on the results of the conducted meta-analysis that included 12 studies and 7449 patients with AF. Determining the concentration of vWF in patients with low risk of stroke development or in those patients with a single non-sex CHA2DS2-VASc score risk factor may be useful in deciding whether to prescribe anticoagulant therapy.

Цель. Оценить взаимосвязь клинических, эхокардиографических показателей и маркеров окислительного стресса с развитием послеоперационной фибрилляции предсердий (ПОФП) у пациентов с ишемической болезнью сердца (ИБС), подвергающихся коронарному шунтированию (КШ). Материал и методы. В рамках исследования "случай-контроль" обследовано 158 пациентов с ИБС, поступивших для проведения КШ. Пациенты разделены на две группы: 1-я группа-без ПОФП (111 больных, 82,0% мужчин, медиана возраста 62,0 [56,0;66,0] года), 2-я группа с ПОФП (47 больных, 84,4% мужчин, медиана возраста 65,0 [61,0;70,0] лет). Медиана развития ПОФП составила 5,2 [2,0;7,0] сут. после КШ. Проводилось исследование содержания супероксиддисмутазы в плазме и в эритроцитах, миелопероксидазы в плазме, каталазы, малонового диальдегида, восстановленного глутатиона (ВГ), глутатионредуктазы (ГР), глутатионпероксидазы (ГПО) в эритроцитах, оксида азота (NO) в плазме, продукты окисления белков. Исследование показателей осуществлялось в предоперационном периоде и в среднем на 3-4 сут. после КШ. Всем пациентам также проводилась эхокардиография. Результаты. После выполнения многофакторного регрессионного анализа отношение шансов развития ПОФП выявлено для следующих показателей: диаметра левого предсердия >41 мм-4,1 (95% доверительный интервал (ДИ),

Atrial fibrillation (AF) is associated with dramatic increasing of stroke risk. Development of this serious complication is accompanied by high mortality and disability. Nowadays we know many different scores that predict stroke risk,butthe most popular is CHA2DS2-VASc risk score. At the same time, this score does not have high predictive accuracyand that is why a lot of modifications with inclusion/deletion of different indicators were introduced.The aim of this review was to estimate the different modifications of CHADS2 и CHA2DS2-VASc scores in predicting stroke risk in patients with AF. In this review R2CHADS2, CHA2DS2-VASc-R, CHA2DS2-VA, mCHA2DS2-VASc and CHA2DS2-VAK scores are evaluated with the use of C-statistics and net reclassification index compared to the original CHA2DS2-VASc score. The search of studies was performed according to PubMed database (https://pubmed.ncbi.nlm.nih.gov/) from 2011 until 2021 years. In this review were included studies written in English with free full text. Literature reviews, books, abstracts books, studies performed on less than 900 patients and studies without C-statistics data available were excluded from this review. Despite of the numerous attempts to improve the quality of CHA2DS2-VASc score, existing modifications nowadays could not become more popular in clinical practice. At the same time, developing of the new score systems, that will have better predictive values in stroke prognosis than CHA2DS2-VASc score, is still an actual problem in modern cardiology.